Hospital
Jefferson Hospital Association INC
Jefferson Hospital Association INC was paid $18.39M by Medicaid between Jan 2018 and Dec 2024, across 341 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 5.2% of everything it billed.
33Billing provider infoJEFFERSON HOSPITAL ASSOCIATION INC
PINE BLUFF, AR 71603
PINE BLUFF, AR 71603
33aNPI1710931985assigned 05/20/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$18.39M
24GClaims1,256,117
24DCodes billed341
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Arkansas
Rank by total paid#1 of 7
Median peer was paid$236K
This provider vs. median78×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 207,526 | $2.32M | |
| 2019 | 251,533 | $3.16M | |
| 2020 | 196,423 | $2.65M | |
| 2021 | 178,908 | $2.72M | |
| 2022 | 181,274 | $3.02M | |
| 2023 | 136,041 | $2.79M | |
| 2024incomplete | 104,412 | $1.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.2% | 15,651 | 9,467 | $965K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.0% | 22,170 | 13,063 | $911K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 7,347 | 6,669 | $706K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 5,156 | 4,677 | $689K |
| 80053 | Comprehensive metabolic panel | 3.5% | 58,927 | 46,930 | $635K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 2,410 | 2,244 | $507K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 24,184 | 4,899 | $492K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.6% | 11,454 | 10,428 | $474K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.6% | 11,466 | 10,438 | $474K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.4% | 10,951 | 9,944 | $439K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.2% | 13,868 | 12,451 | $409K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 5,048 | 4,113 | $406K |
329 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 24,102 | $401K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 57,133 | $387K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.1% | 31,991 | $386K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 3,554 | $345K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.8% | 2,477 | $340K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 32,386 | $256K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 21,629 | $254K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.3% | 39,613 | $247K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 17,696 | $241K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 10,750 | $216K |
| 99285 | Emergency room visit (most serious) | 1.1% | 9,245 | $207K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 1.1% | 18,579 | $196K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.0% | 923 | $191K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.0% | 784 | $186K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,191 | $163K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,163 | $162K |
| 86901 | <1% | 6,335 | $155K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,493 | $148K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,482 | $129K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 967 | $127K |
| 84484 | <1% | 17,315 | $118K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,894 | $115K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,523 | $115K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,829 | $114K |
| 83880 | <1% | 5,676 | $113K | |
| 87088 | <1% | 14,277 | $113K | |
| 87486 | <1% | 2,415 | $109K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,840 | $109K |
| 87581 | <1% | 2,413 | $109K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,373 | $109K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,617 | $108K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,381 | $107K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,416 | $106K |
| 85027 | <1% | 21,422 | $103K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,405 | $103K |
| 81001 | <1% | 34,110 | $101K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,208 | $98K |
| 99283 | Emergency room visit (moderate) | <1% | 1,885 | $95K |
| 82553 | <1% | 11,677 | $94K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,825 | $93K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,241 | $87K |
| 36415 | Collection of venous blood by venipuncture | <1% | 66,556 | $81K |
| 82550 | <1% | 16,812 | $79K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,110 | $79K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,144 | $78K |
| 80061 | Lipid panel | <1% | 8,682 | $77K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,171 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,536 | $74K |
| 80050 | General health panel | <1% | 1,537 | $71K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,798 | $70K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,681 | $69K |
| 83735 | <1% | 15,270 | $68K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,386 | $63K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,539 | $63K |
| 74018 | <1% | 4,346 | $62K | |
| 82805 | <1% | 2,828 | $62K | |
| 84703 | <1% | 7,055 | $61K | |
| 36430 | <1% | 810 | $60K | |
| 87040 | <1% | 7,336 | $60K | |
| 87077 | <1% | 6,623 | $60K | |
| 82948 | <1% | 13,714 | $59K | |
| 81025 | <1% | 7,563 | $58K | |
| 97161 | <1% | 1,787 | $57K | |
| 87653 | <1% | 1,266 | $56K | |
| 86703 | <1% | 3,580 | $56K | |
| 96367 | <1% | 1,846 | $56K | |
| 59025 | Fetal non-stress test | <1% | 374 | $55K |
| 83690 | <1% | 8,093 | $52K | |
| 99284 | Emergency room visit (serious) | <1% | 1,367 | $49K |
| 86885 | <1% | 5,566 | $48K | |
| 86922 | <1% | 1,428 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,201 | $46K |
| 87807 | <1% | 3,875 | $45K | |
| 84439 | <1% | 7,255 | $44K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 885 | $44K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,964 | $44K |
| 83605 | <1% | 5,418 | $44K | |
| 73564 | <1% | 1,814 | $44K | |
| 84702 | <1% | 4,355 | $43K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,019 | $42K |
| 82150 | <1% | 7,004 | $42K | |
| 84145 | <1% | 2,827 | $42K | |
| 87070 | <1% | 4,248 | $41K | |
| 86762 | <1% | 2,296 | $38K | |
| 73630 | <1% | 1,987 | $37K | |
| 72141 | <1% | 174 | $37K | |
| 85730 | <1% | 8,735 | $37K | |
| 73030 | <1% | 2,291 | $37K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,947 | $36K |
| 82677 | <1% | 1,066 | $32K | |
| 87340 | <1% | 2,779 | $32K | |
| 82105 | <1% | 1,583 | $32K | |
| 87186 | <1% | 5,471 | $32K | |
| 85610 | <1% | 11,121 | $31K | |
| 94760 | <1% | 3,605 | $31K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 85 | $31K |
| 73130 | <1% | 1,799 | $30K | |
| 94664 | <1% | 9,578 | $30K | |
| 70486 | <1% | 219 | $29K | |
| 72100 | <1% | 1,609 | $28K | |
| 74022 | <1% | 1,449 | $27K | |
| 86900 | <1% | 6,336 | $26K | |
| 73610 | <1% | 1,605 | $26K | |
| 83615 | <1% | 5,296 | $24K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,366 | $24K |
| 73221 | <1% | 117 | $23K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 778 | $23K |
| 93017 | <1% | 1,260 | $23K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,966 | $22K |
| 85379 | <1% | 2,720 | $22K | |
| 73562 | <1% | 952 | $21K | |
| 86336 | <1% | 1,065 | $20K | |
| 77066 | Tomosynthesis, mammo | <1% | 377 | $20K |
| 82565 | <1% | 2,505 | $19K | |
| 82728 | <1% | 2,077 | $19K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,492 | $19K |
| 76642 | <1% | 846 | $19K | |
| 93458 | <1% | 280 | $18K | |
| 86592 | <1% | 3,739 | $18K | |
| 82607 | <1% | 1,882 | $18K | |
| 95819 | <1% | 482 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 99 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,154 | $17K |
| 20610 | <1% | 466 | $17K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 79 | $17K |
| 73502 | <1% | 1,258 | $17K | |
| 93971 | <1% | 511 | $16K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 570 | $16K |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 13 | $16K |
| 94729 | <1% | 981 | $16K | |
| 86677 | <1% | 1,391 | $15K | |
| 99152 | <1% | 2,850 | $15K | |
| 82248 | <1% | 3,332 | $15K | |
| 94726 | <1% | 996 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,310 | $14K |
| 71250 | <1% | 176 | $14K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,217 | $14K |
| 94060 | <1% | 975 | $14K | |
| 83550 | <1% | 3,064 | $14K | |
| 90714 | <1% | 1,539 | $13K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,276 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,035 | $13K |
| 72040 | <1% | 665 | $13K | |
| 96376 | <1% | 4,748 | $13K | |
| 84153 | <1% | 994 | $13K | |
| 76937 | <1% | 541 | $13K | |
| 86803 | <1% | 773 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $12K |
| 80177 | <1% | 988 | $12K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 407 | $11K |
| 76000 | <1% | 809 | $11K | |
| 83540 | <1% | 3,303 | $11K | |
| 88342 | <1% | 372 | $11K | |
| 76801 | <1% | 320 | $11K | |
| 82950 | <1% | 1,813 | $11K | |
| 73110 | <1% | 618 | $11K | |
| 85660 | <1% | 1,634 | $11K | |
| 80076 | <1% | 1,842 | $10K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,128 | $9K |
| 97016 | <1% | 7,028 | $9K | |
| 80164 | <1% | 729 | $9K | |
| 81002 | <1% | 2,255 | $8K | |
| 85652 | <1% | 4,312 | $8K | |
| 71010 | <1% | 3,988 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 227 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,267 | $8K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,275 | $8K |
| 76536 | <1% | 284 | $8K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,583 | $7K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 183 | $7K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 85 | $7K |
| 74220 | <1% | 181 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,705 | $7K |
| 71020 | <1% | 1,091 | $7K | |
| 84550 | <1% | 2,274 | $7K | |
| 95885 | <1% | 339 | $7K | |
| 82746 | <1% | 701 | $7K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 33 | $7K |
| 83970 | <1% | 465 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,583 | $7K |
| 86140 | <1% | 1,566 | $7K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 259 | $6K |
| 73560 | <1% | 399 | $6K | |
| 80069 | <1% | 1,406 | $6K | |
| 83021 | <1% | 312 | $6K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,358 | $6K |
| 80074 | <1% | 126 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,974 | $5K |
| 74420 | <1% | 225 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 273 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 212 | $5K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 282 | $5K |
| 74000 | <1% | 1,344 | $5K | |
| 82947 | <1% | 1,100 | $5K | |
| 82570 | <1% | 1,285 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 244 | $4K |
| 73590 | <1% | 220 | $4K | |
| 36600 | <1% | 2,558 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 129 | $4K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 95 | $4K |
| 72110 | <1% | 119 | $4K | |
| 85018 | <1% | 2,468 | $4K | |
| 77062 | <1% | 116 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,861 | $4K |
| 36591 | <1% | 335 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 161 | $3K |
| 86038 | <1% | 331 | $3K | |
| 74178 | <1% | 44 | $3K | |
| 84100 | <1% | 1,879 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,776 | $3K |
| 85014 | <1% | 1,697 | $3K | |
| 84481 | <1% | 240 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,548 | $3K |
| 85045 | <1% | 763 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 57 | $3K |
| 84156 | <1% | 914 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,135 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,029 | $2K |
| 76770 | <1% | 135 | $2K | |
| 85049 | <1% | 104 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 148 | $2K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 252 | $2K |
| 83655 | <1% | 145 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 69 | $2K |
| 84520 | <1% | 669 | $2K | |
| 93970 | <1% | 58 | $2K | |
| 77001 | <1% | 86 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,482 | $2K |
| 96417 | <1% | 56 | $2K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 28 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 295 | $1K |
| 73140 | <1% | 104 | $1K | |
| 72190 | <1% | 60 | $1K | |
| 86696 | <1% | 36 | $1K | |
| C1769 | Guide wire | <1% | 1,044 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 30 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,047 | $1K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 233 | $1K |
| 84480 | <1% | 102 | $1K | |
| 73700 | <1% | 13 | $1K | |
| 97162 | <1% | 55 | $1K | |
| 94761 | <1% | 132 | $1K | |
| 77080 | <1% | 12 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 368 | $1K |
| 52005 | <1% | 17 | $1K | |
| 51610 | <1% | 59 | $1K | |
| 73552 | <1% | 92 | $990.55 | |
| 72170 | <1% | 55 | $989.26 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,182 | $915.49 |
| 97035 | <1% | 1,154 | $902.62 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,377 | $862.55 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,278 | $732.67 |
| 87320 | <1% | 81 | $720.72 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $713.16 |
| 73090 | <1% | 44 | $684.50 | |
| 87210 | <1% | 176 | $675.18 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 940 | $667.46 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 80 | $663.84 |
| 86695 | <1% | 36 | $657.72 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 117 | $651.58 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 772 | $629.02 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,218 | $623.43 |
| 74021 | <1% | 36 | $620.76 | |
| 87205 | <1% | 133 | $581.49 | |
| 86704 | <1% | 48 | $572.00 | |
| 73080 | <1% | 42 | $566.25 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 98 | $517.23 |
| S0028 | Injection, famotidine, 20 mg | <1% | 136 | $494.68 |
| 86706 | <1% | 48 | $479.89 | |
| 78264 | <1% | 17 | $471.90 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 107 | $440.93 |
| 86431 | <1% | 92 | $374.68 | |
| 86160 | <1% | 25 | $370.83 | |
| 84132 | <1% | 175 | $363.48 | |
| 85007 | <1% | 351 | $357.24 | |
| 96415 | <1% | 104 | $343.86 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 756 | $338.98 |
| 84450 | <1% | 87 | $332.25 | |
| 85347 | <1% | 30 | $332.13 | |
| 84460 | <1% | 87 | $331.73 | |
| 87075 | <1% | 16 | $305.01 | |
| 97014 | <1% | 2,119 | $273.14 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 190 | $272.00 |
| 88300 | <1% | 46 | $270.00 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 718 | $261.93 |
| 74010 | <1% | 134 | $261.84 | |
| 87400 | <1% | 20 | $243.30 | |
| 86708 | <1% | 14 | $230.83 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 241 | $205.00 |
| 86200 | <1% | 16 | $198.24 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 376 | $179.35 |
| 94618 | <1% | 29 | $164.58 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 404 | $148.63 |
| 82010 | <1% | 30 | $142.84 | |
| 80320 | <1% | 13 | $135.72 | |
| 97166 | <1% | 59 | $129.45 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 727 | $128.10 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,169 | $125.15 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 148 | $119.97 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 108 | $119.46 |
| 86705 | <1% | 13 | $113.05 | |
| 92611 | <1% | 26 | $109.28 | |
| 71101 | <1% | 13 | $102.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $93.72 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 31 | $71.56 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 40 | $65.32 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 339 | $51.85 |
| 82043 | <1% | 13 | $43.47 | |
| 84134 | <1% | 19 | $41.66 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 605 | $40.45 |
| 0001A | <1% | 112 | $33.11 | |
| 0002A | <1% | 100 | $31.60 | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 330 | $23.07 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 101 | $22.02 |
| 96523 | <1% | 17 | $20.94 | |
| G0378 | Hospital observation service, per hour | <1% | 1,256 | $13.69 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 21 | $12.40 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 14 | $8.17 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 150 | $3.52 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 122 | $0.29 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 79 | $0.18 |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 27 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 198 | $0.00 |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 14 | $0.00 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | 0% | 630 | $0.00 |
| 76942 | 0% | 72 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 93 | $0.00 |
| 0003A | 0% | 28 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, KRISTEN (DIRECTOR OF REIMBURSEMENT)